Clinical Trials Logo

Alzheimers Disease clinical trials

View clinical trials related to Alzheimers Disease.

Filter by:

NCT ID: NCT01469351 Completed - Alzheimers Disease Clinical Trials

Identifying Potential Effects of Liraglutide on Degenerative Changes

Start date: January 2012
Phase: N/A
Study type: Interventional

Today Alzheimers disease can not be cured. Animal experiments have shown that the hormone GLP-1 can improve memory in Alzheimer-prone mice. The investigators hypothesis is that a 6-month treatment with the GLP-1 receptor stimulating drug liraglutide will reduce the intracerebral amyloid deposition in the central nervous system (CNS) in patients with Alzheimer's disease (AD) and thereby reduce the clinical symptoms of the disease.

NCT ID: NCT00911690 Completed - Dementia Clinical Trials

Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders

Start date: July 2009
Phase: N/A
Study type: Observational

This study is collecting tissue specimens (blood, urine and saliva) from up to 1000 patients, with and without cognitive disorders, to store in the Bio Bank for future research. The specimens could be used in future research projects that could help improve the accuracy of diagnosis of a disease, predict who might develop a disease, help monitor the disease, or improve the understanding of the disease. Patients are only being recruited from Beaumont Hospitals Geriatric Clinic.

NCT ID: NCT00456417 Completed - Alzheimers Disease Clinical Trials

Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects

Start date: April 2007
Phase: Phase 1
Study type: Interventional

The underlying goal of this study is to assess 123-I MNI-187 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.

NCT ID: NCT00448799 Completed - Alzheimers Disease Clinical Trials

Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls

Start date: March 2007
Phase: Phase 1
Study type: Interventional

The underlying goal of this study is to assess 123-I AV83 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.

NCT ID: NCT00439010 Completed - Alzheimers Disease Clinical Trials

Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects

Start date: February 2007
Phase: Phase 1
Study type: Interventional

The underlying goal of this study is to assess 123-I AV39 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.